0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Reviews |

Atherosclerotic Renovascular Disease and Progressive Renal Failure

Jeffrey M. Rimmer, MD; and F. John Gennari, MD
[+] Article and Author Information

From University of Vermont College of Medicine, Burlington, Vermont. Requests for Reprints: Jeffrey M. Rimmer, MD, D305 Given Building, University of Vermont College of Medicine, Burlington, VT 05405. Acknowledgment: The authors thank Dr. Harriet Dustan for her helpful comments.


Copyright 2004 by the American College of Physicians


Ann Intern Med. 1993;118(9):712-719. doi:10.7326/0003-4819-118-9-199305010-00010
Text Size: A A A

Purpose: To evaluate information on the prevalence and rate of progression of atherosclerotic renovascular disease and the effect of angiotensin-converting enzyme inhibition on this process, with the goal of developing a rational approach to the diagnosis and management of this disorder.

Data Sources: Relevant articles were identified from the authors' files and from MEDLINE searches. Additional references were obtained from the bibliographies of identified articles.

Study Selection: Virtually no controlled prospective studies have been reported. The articles presented are primarily retrospective analyses and include those that provide sufficient information about the incidence or progression of renovascular disease and about the outcome and mortality rate associated with various treatments, to allow evaluation.

Data Extraction: For the outcomes of interest, data from individual reports are presented in tabular form, the results summed, and averages obtained.

Results: Atherosclerotic renovascular disease, in many cases involving both renal arteries, is a common finding in patients older than 50 years, particularly those with diffuse atherosclerotic vascular disease. Hypertension is not a particularly sensitive indicator of this disease (almost one half are not hypertensive). The disease progresses and may account for 5% to 15% of all patients developing end-stage renal disease each year. Angiotensin-converting enzyme inhibition may damage ischemic renal tissue, but this is counterbalanced by beneficial effects of this therapy. Once end-stage renal disease is present, mortality rates are high despite dialysis support (> 50% over 3 years). Both surgery and angioplasty can preserve or improve renal function and may delay or prevent the need for dialysis therapy. These invasive procedures may have lower rates of morbidity and mortality than the so-called conservative approach of dialysis therapy when renal failure develops.

Conclusions: Given available information, diagnosis and intervention should be considered seriously in patients at high risk for renovascular disease who have clearly progressing renal insufficiency. Prospective trials are needed, however, to determine the costs and benefits of each approach to treatment in all patients with renovascular disease and renal insufficiency.

Figures

Grahic Jump Location
Figure 1.
Potential effect of angiotensin-converting enzyme inhibition on glomerular filtration rate (GFR) and serum creatinine concentration (SCR) in patients with hemodynamically significant renal artery stenosis.

(Left) The effect in the setting of bilateral stenosis. (Middle) The effect in the setting of unilateral stenosis with contralateral parenchymal disease (gray area). (Right) The effect in the setting of unilateral stenosis with a normal contralateral kidney.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)